Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > TLD1433 and Conjunctive Melanoma (CM)

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Sep 20, 2021 7:30pm

223 Views

Post# 33890520

RE:RE:TLD1433 and Conjunctive Melanoma (CM)

Eoganacht wrote: It's not just melanoma. TLD1433 has been demonstrated to be effective in the treatment of numerous other types of cancer besides GBM and NSCLC. Unfortunately, Theralase has limited resources. Clinical trials are expensive and Theralase has so far only raised enough money to pay for the current phase 2 trial. I hope that one day Theralase, (or the company that buys Theralase), will be able to realize some of the potential of the research waiting in the wings. These are some examples.

Sept. 5, 2017 - Theralase Anti-Cancer Drugs Effective in the Destruction of Cervical Cancer

Sept. 19, 2017 - Theralase Lead Anti-Cancer Drug Effective in the Destruction of Throat Cancer

Nov. 22, 2017 - Theralase® Anti-Cancer Vaccine Validated in Colorectal Cancer

Oct. 9, 2018 - Theralase® Anti-Cancer Technology Shows Promise for Esophageal Cancer Using Targeted Molecular Delivery System

socksnblonds642 wrote:
Wonder why no more mention of proving TLD1433 as a cure for CM. Was there a downside that maybe I missed? If not then CM should have been listed with the lung and brain cancers. A year and a half and I can't find anything new on CM and TLD1433. Did it progress from Zebra fish? Did the company ever promote this? Wonder why it went nowhere.

Anyone? Bueller? Bueller

(I hope hockey starts soon...)

https://pubmed.ncbi.nlm.nih.gov/32143295/

The research paper was pretty clear:

"Based on our results, we suggest repurposing of TLD1433 for treatment of incurable CM and further testing in alternative pre-clinical models."

And looking at the dates it is always nice to know that there is never any urgency in resolving any of this cancer stuff. Not like a warp speed for a covid vaccine. But that's alright, cancer has been around for years -- it's effects in death and such are just considered normal, standard fare.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand